Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CMO Sells 603 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE) CMO Jane Huang sold 603 shares of BeiGene stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $351.55, for a total value of $211,984.65. Following the completion of the transaction, the chief marketing officer now directly owns 284,933 shares of the company’s stock, valued at $100,168,196.15. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jane Huang also recently made the following trade(s):

  • On Tuesday, June 1st, Jane Huang sold 540 shares of BeiGene stock. The shares were sold at an average price of $362.64, for a total value of $195,825.60.
  • On Friday, May 28th, Jane Huang sold 1,500 shares of BeiGene stock. The shares were sold at an average price of $356.30, for a total value of $534,450.00.
  • On Thursday, April 29th, Jane Huang sold 1,500 shares of BeiGene stock. The shares were sold at an average price of $354.92, for a total value of $532,380.00.
  • On Monday, March 29th, Jane Huang sold 1,500 shares of BeiGene stock. The shares were sold at an average price of $324.00, for a total value of $486,000.00.

Shares of BGNE opened at $352.99 on Friday. The company has a 50 day simple moving average of $328.70. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.62 and a quick ratio of 4.56. The firm has a market capitalization of $32.41 billion, a P/E ratio of -25.90 and a beta of 0.87. BeiGene, Ltd. has a 52-week low of $155.16 and a 52-week high of $388.97.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Friday, May 7th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.90) by $2.59. BeiGene had a negative return on equity of 31.71% and a negative net margin of 135.24%. On average, equities research analysts predict that BeiGene, Ltd. will post -11.88 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of BGNE. Marshall Wace North America L.P. purchased a new stake in BeiGene in the first quarter valued at approximately $76,000. Amundi Pioneer Asset Management Inc. lifted its stake in BeiGene by 9.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 17,001 shares of the company’s stock valued at $2,244,000 after buying an additional 1,500 shares during the last quarter. NN Investment Partners Holdings N.V. lifted its stake in BeiGene by 67.6% in the fourth quarter. NN Investment Partners Holdings N.V. now owns 11,400 shares of the company’s stock valued at $2,945,000 after buying an additional 4,600 shares during the last quarter. Parallel Advisors LLC lifted its stake in BeiGene by 35.0% in the fourth quarter. Parallel Advisors LLC now owns 135 shares of the company’s stock valued at $35,000 after buying an additional 35 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in BeiGene by 16.1% in the fourth quarter. First Trust Advisors LP now owns 6,386 shares of the company’s stock valued at $1,650,000 after buying an additional 887 shares during the last quarter. Institutional investors own 61.50% of the company’s stock.

A number of equities analysts have recently commented on BGNE shares. China Renaissance Securities started coverage on BeiGene in a research report on Monday, March 8th. They set a “buy” rating for the company. HSBC boosted their price objective on BeiGene from $296.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, March 16th. Zacks Investment Research raised BeiGene from a “sell” rating to a “hold” rating in a research report on Tuesday, May 11th. Cowen boosted their price objective on BeiGene from $348.00 to $429.00 and gave the stock an “outperform” rating in a research report on Thursday, February 18th. Finally, CLSA downgraded BeiGene from an “outperform” rating to an “underperform” rating and lowered their price objective for the stock from $330.00 to $321.00 in a research report on Monday, March 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $322.33.

BeiGene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Story: Pattern Day Trader – What is the PDT Rule?

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.